Ibrutinib, a first-generation inhibitor of BTK, was approved in 2013 and has shown noteworthy clinical activity in lymphoid malignancies, such as chronic lymphocytic leukaemia (CLL) [5] and mantle cell lymphoma (MCL) [6]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.